Market failure and the poverty of new drugs in maternal health

PLoS Medicine

Volumn 5, Issue 1, 2008, Pages 0022-0028

  Fisk, Nicholas M ^b   Atun, Rifat ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AS 602305; ATOSIBAN; BARUSIBAN; BEODORADINE SULFATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; CYTOKINE RECEPTOR AGONIST; DIGOXIN ANTIBODY; DIGOXIN ANTIBODY F(AB) FRAGMENT; GESTIVA; HYDROXYPROGESTERONE CAPROATE; LJP 1082; MISOPROSTOL; OXYTOCIN ANTAGONIST; PROGESTERONE; PV 903; RELAXIN; SAR 150640; SSR 126768; UNCLASSIFIED DRUG; CARDIOVASCULAR AGENT; NEW DRUG;

AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CLINICAL TRIAL; DRUG INDUSTRY; DRUG MECHANISM; DRUG RESEARCH; HEALTH CARE; HUMAN; MATERNAL CARE; MATERNAL DISEASE; MATERNAL WELFARE; PERINATAL MORBIDITY; PREGNANCY; COMPARATIVE STUDY; CONGENITAL MALFORMATION; DRUG SCREENING; ECONOMICS; EUROPE; FACTUAL DATABASE; FEMALE; FINANCIAL MANAGEMENT; MARKETING; PREGNANCY COMPLICATION; RESEARCH; RISK; STATISTICS; UNITED STATES;

ABNORMALITIES, DRUG-INDUCED; AMYOTROPHIC LATERAL SCLEROSIS; CARDIOVASCULAR AGENTS; DATABASES, FACTUAL; DRUG EVALUATION; DRUG EVALUATION, PRECLINICAL; DRUG INDUSTRY; DRUGS, INVESTIGATIONAL; EUROPE; FEMALE; FINANCIAL SUPPORT; HUMANS; MARKETING; MATERNAL WELFARE; PREGNANCY; PREGNANCY COMPLICATIONS; RESEARCH; RISK; UNITED STATES;

EID: 38849113780     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.0050022     Document Type: Article

References (35)

1. Bartlett S (2007) A-Z of medicines research. London: The Association of the British Pharmaceutical Industry.
2. Lacroix I, Damase-Michel C, Lapeyre-Mestre M, Montastruc JL (2000) Prescription of drugs during pregnancy in France. Lancet 356: 1735-1736.
3. Thornton J (2003) The drugs we deserve. BJOG 110: 969-970.
4. Peppin P (2003) Manufacturing uncertainty: adverse effects of drug development for women. Int J Law Psychiatry 26: 515-532.
5. Chalmers I, Enkin M, Keirse MJ, editors (1989) Effective care in pregnancy and childbirth. Oxford: Oxford University Press.
6. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ (2006) Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 367: 1747-1757.
7. World Health Organization (2007) Maternal mortality in 2005: estimates developed by WHO, UNICEF, UNFPA and The World Bank. Available: http://www.who.int/reproductivehealth/publications/maternal_mortality_2005/ index.html. Accessed 18 December 2007.
8. Stanton C, Lawn JE, Rahman H, Wilczynska-Ketende K, Hill K (2006) Stillbirth rates: delivering estimates in 190 countries. Lancet 367: 1487-1494.
9. Graham W, Cairns Bhattacharya J, Bullough C, Quayyum Z, Rogo K (2006) Maternal and perinatal conditions. In: Jamison DT, Measham A, Alleyne G, Claeson M, Evans D, et al., editors. Disease Control Priorities in Developing Countries. 2nd edition. Available: http://www.dcp2.org/pubs/DCP/26/FullText. Accessed 18 December 2007.
10. United Nations General Assembly (2000) United Nations Millennium Declaration. A/RES/55/2. Available: http://www.un.org/millennium/declaration/ ares552e.htm. Accessed 18 December 2007.
11. United Nations (2007) The Millennium Development Goals report. Available: http://www.un.org/millenniumgoals/pdf/mdg2007.pdf. Accessed 18 December 2007.
12. Pecoul B, Chirac P, Trouiller P, Pinel J (1999) Access to essential drugs in poor countries: a lost battle? JAMA 281: 361-367.
13. Moran M, Ropars A-L, Guzman J, Diaz J, Garrison C (2005) The new landscape of neglected disease drug development. LSE Health and Social Care, The Wellcome Trust. Available: http://www.wellcome.ac.uk/assets/wtx026592.pdf. Accessed 18 December 2007.
14. Beghi E, Logroscino G, Chio A, Hardiman O, Mitchell D, et al. (2006) The epidemiology of ALS and the role of population-based registries. Biochim Biophys Acta 1762: 1150-1157.
15. Pharmaceutical Research and Manufacturers of America (2006) Pharmaceutical industry profile 2006. Available: http://www.phrma.org/files/ 2006%20Industry%20Profile.pdf. Accessed 18 December 2007.
16. Kaplan W, Laing R (2004) Priority medicines for Europe and the World. World Health Organization, Department of Essential Drugs and Medicines Policy. Available: http://mednet3.who.int/prioritymeds/report/final18october.pdf. Accessed 18 December 2007.
17. Altman D, Carroli G, Duley L, Farrell B, Moodley J, et al. (2002) Do women with preeclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet 359: 1877-1890.
18. Sevene E, Lewin S, Mariano A, Woelk G, Oxman AD, et al. (2005) System and market failures: the unavailability of magnesium sulphate for the treatment of eclampsia and pre-eclampsia in Mozambique and Zimbabwe. BMJ 331: 765-769.
19. Lo WY, Friedman JM (2002) Teratogenicity of recently introduced medications in human pregnancy. Obstet Gynecol 100: 465-473.
20. Hamilton BE, Martin JA, Ventura SJ (2006) Births: Preliminary data for 2005. National Center for Health Statistics, Centers for Disease Control and Prevention. Available: http://www.cdc.gov/nchs/products/pubs/pubd/hestats/ prelimbirths05/prelimbirths05.htm. Accessed 18 December 2007.
21. Lanzieri G, Corsini V (2006) Statistics in Focus: First demographic estimates for 2005. Eurostat. Available: http://epp.eurostat.cec.eu.int/portal/ page?_pageid=1073,46587259&_dad=portal&_schema=PORTAL& p_product_code=KS-NK-06-001. Accessed 18 December 2007.
22. Cutler DM (2007) The demise of the blockbuster? N Engl J Med 356: 1292-1293.
23. Owens J (2007) 2006 drug approvals: finding the niche. Nat Rev Drug Discov 6: 99-101.
24. Fisk NM, Shennan AH (1993) Litigation and prescribing drugs for unlicensed indications. Lancet 341: 1218.
25. Worldwide Atosiban versus Beta-Agonists Study Group (2001) Effectiveness and safety of the oxytocin antagonist atosiban versus beta-adrenergic agonists in the treatment of preterm labour. BJOG 108: 133-142.
26. Fisk NM, Chan J (2003) The case for tocolysis in threatened preterm labour. BJOG 110: 98-102.
27. Turner S, Longworth A, Nunn AJ, Choonara I (1998) Unlicensed and off label drug use in paediatric wards: prospective study. BMJ 316: 343-345.
28. Costello A, Filippi V, Kubba T, Horton R (2007) Research challenges to improve maternal and child survival. Lancet 369: 1240-1243.
29. Ceci A, Felisi M, Baiardi P, Bonifazi F, Catapano M, et al. (2006) Medicines for children licensed by the European Medicines Agency (EMEA): the balance after 10 years. Eur J Clin Pharmacol 62: 947-952.
30. Balakrishnan K, Grieve J, Tordoff J, Norris P, Reith D (2006) Pediatric licensing status and the availability of suitable formulations for new medical entities approved in the United States between 1998 and 2002. J Clin Pharmacol 46: 1038-1043.
31. World Health Organization (2006) Joint WHO-UNICEF Expert Consultation on Paediatric Essential Medicines. Available: http://ipaworld. org/news/news/ ReportMeetingWHO-UNICEF2006. pdf. Accessed 18 December 2007.
32. Berndt E GR, Kremer M, Lee J, Levine R, Weizsacker G, et al. (2006) Advance Market Commitments for Vaccines Against Neglected Disease: Estimating Costs and Effectiveness. Working Paper Number 98 Washington DC: Center for Global Development.
33. Horesh R (2007) What are social policy bonds? Available: http://socialgoals.com/index.htm. Accessed 18 December 2007.
34. United Kingdom Department of Health (2004) New initiative to develop medicines for children. Available: http://www.dh.gov.uk/en/ Publicationsandstatistics/Pressreleases/DH_4087889. Accessed 18 December 2007.
35. European Economic Community (1992) Council Regulation (EEC) No. 1768/92 of 18 June 1992 concerning the creation of a supplementary protection certificate for medicinal products. Available: http://eur-lex.europa.eu/ smartapi/cgi/sga_doc?smartapi!c elexapi!prod!CELEXnumdoc&numdoc= 31992R1768&model=guichett&lg=en. Accessed 18 December 2007.